Vireo Growth Inc. (VREOF): Entry into a Material Definitive Agreement
Vireo Growth Inc. (VREOF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 tm2621363d5_10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT by and among VIREO GROWTH INC., SB OHIO HOLDINGS INC., CHICAGO ATLANTIC CREDIT OPPORTUNITIES, LLC, and FARMACEUTICALRX LLC, Dated as of July 30, 2026 Table of Contents Page(s) ARTICLE I. DEFINI
How this was made
The 30-second read
Why it matters
This disclosure can change expectations for Vireo’s balance sheet and ownership structure through a convertible notes conversion and subsequent purchase of company securities, affecting dilution and risk premium until closing.
Market read
A material definitive agreement filing is a concrete, deal-driven catalyst that can reprice the stock based on deal economics and closing probability.
What to watch
Traders should focus on closing conditions, regulatory approvals, and the actual consideration mechanics (cash vs shares, deferred payments, forfeiture terms), which are not included in the excerpt.
Background
The 8-K indicates Vireo Growth entered a material definitive securities purchase agreement dated July 30, 2026, involving SB Ohio Holdings, Chicago Atlantic Credit Opportunities, and FarmaceuticalRx.
Ticker impact
Vireo Growth filed an 8-K disclosing entry into a material definitive securities purchase agreement tied to a company ownership and note-conversion structure.
Near-term volatility is possible around deal terms, closing conditions, and any subsequent amendments or financing details; direction depends on purchase price, consideration mix, and closing probability.
The article is a primary SEC disclosure of a material definitive agreement, but the provided excerpt does not include key economic terms (purchase price, share issuance amounts, or closing timeline), limiting precision on magnitude and direction.
Market effects
Cannabis-adjacent financing and regulatory-compliance covenants can influence perceived risk for similarly structured issuers, though this is company-specific.
Limited direct regional spillover; impact is primarily on the issuer’s capital structure and deal counterparties.
Low global relevance; this is a private-party securities transaction disclosed via SEC filing.
Counterpoint
If the agreement implies significant dilution or unfavorable economics, the market could interpret the filing as a funding overhang rather than a positive catalyst.
Key entities
- companyVireo Growth Inc.
Buyer in the securities purchase agreement disclosed in the 8-K.
- companySB Ohio Holdings Inc.
Seller holding 100% of the Company’s membership interests prior to closing, per the agreement recital.
- companyChicago Atlantic Credit Opportunities, LLC
Seller and party whose convertible notes are referenced for conversion into membership interests.
- companyFarmaceuticalRx LLC
Seller party to the securities purchase agreement.
